N Engl J Med. 1980 Oct 2;303(14):782-7.

Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa.

Sternberg EM, Van Woert MH, Young SN, Magnussen I, Baker H, Gauthier S, Osterland CK.

Abstract

A scleroderma-like illness developed in a patient treated with L-5 hydroxytryptophan (L-5HTP) and carbidopa for intention myoclonus. The patient had high plasma kynurenine levels that remained high when the L-5HTP-carbidopa combination was discontinued, However, levels rose futher on drug rechallenge, suggesting that the drug unmasked an abnormality in one of the enzymes that catabolize kynurenine. Plasma kynurenine was also determined to be high in seven of 15 patients wth idiopathic scleroderma, but not in eight patients with intention myoclonus treated with L-5HTP and a decarboxylase inhibitor and in whom scleroderma did not develop or in 10 patients with Parkinson's disease treated wth L-dopa and carbidopa. Our data and studies in the literature suggest that two factors may be important in the pathogenesis of some scleroderma-like illness: high plasma serotonin and the abnormality associated with elevated kynurenine.

PMID:: 6997735; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Medical

Scleroderma - MedlinePlus Health Information

Molecular Biology Databases

Supplemental Content

Related citations

Long-term therapy of myoclonus and other neurologic disorders with L-5-hydroxytryptophan and carbidopa. [N Engl J Med. 1977]
Long-term therapy of myoclonus and other neurologic disorders with L-5-hydroxytryptophan and carbidopa.
Van Woert MH, Rosenbaum D, Howieson J, Bowers MB Jr. N Engl J Med. 1977 Jan 13; 296(2):70-5.
Drug-related scleroderma-like illness. The Fine page. [Int J Dermatol. 1981]
Drug-related scleroderma-like illness. The Fine page.
Fine RM. Int J Dermatol. 1981 Jun; 20(5):354.
Therapy of intention myoclonus with L-5-hydroxytryptophan and a peripheral decarboxylase inhibitor, MK 486. [Neurology. 1975]
Therapy of intention myoclonus with L-5-hydroxytryptophan and a peripheral decarboxylase inhibitor, MK 486.
Van Woert MH, Sethy VH. Neurology. 1975 Feb; 25(2):135-40.
Review [Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination]. [Neurologia. 2005]
Review [Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].
Castro A, Valldeoriola F, Linazasoro G, Rodriguez-Oroz MC, Stochi F, Marin C, Rodriguez M, Vaamonde J, Jenner P, Alvarez L, et al. Neurologia. 2005 May; 20(4):180-8.
Review Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo). [Expert Rev Neurother. 2004]
Review Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo).
Silver DE. Expert Rev Neurother. 2004 Jul; 4(4):589-99.

See reviews... See all...

Cited by 10 PubMed Central articles

Pathological and immunological effects of ingesting L-tryptophan and 1,1'-ethylidenebis (L-tryptophan) in Lewis rats. [J Clin Invest. 1993]
Pathological and immunological effects of ingesting L-tryptophan and 1,1'-ethylidenebis (L-tryptophan) in Lewis rats.
Love LA, Rader JI, Crofford LJ, Raybourne RB, Principato MA, Page SW, Trucksess MW, Smith MJ, Dugan EM, Turner ML. J Clin Invest. 1993 Mar; 91(3):804-11.
Review Systemic sclerosis--a microvascular disorder? [J R Soc Med. 1983]
Review Systemic sclerosis--a microvascular disorder?
Jayson MI. J R Soc Med. 1983 Aug; 76(8):635-42.
L-tryptophan implicated in human eosinophilia-myalgia syndrome causes fasciitis and perimyositis in the Lewis rat. [J Clin Invest. 1990]
L-tryptophan implicated in human eosinophilia-myalgia syndrome causes fasciitis and perimyositis in the Lewis rat.
Crofford LJ, Rader JI, Dalakas MC, Hill RH Jr, Page SW, Needham LL, Brady LS, Heyes MP, Wilder RL, Gold PW. J Clin Invest. 1990 Nov; 86(5):1757-63.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound
PubChem chemical compound records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records. Multiple substance records may contribute to the PubChem compound record.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance
PubChem chemical substance records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Development of a scleroderma-like illness during therapy with L-5-hydroxytryptop...
Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa.
N Engl J Med. 1980 Oct 2 ;303(14):782-7.

PubMed
Central serotonergic stimulation of aldosterone secretion.
Central serotonergic stimulation of aldosterone secretion.
J Clin Invest. 1985 Oct ;76(4):1485-90.

PubMed
On the tryptophan-serotonin metabolism in manic-depressive disorders. Changes in...
On the tryptophan-serotonin metabolism in manic-depressive disorders. Changes in plasma 5-HT and 5-HIAA levels and urinary 5-HIAA excretion following oral loading of L-5HTP in patients with depression.
Hiroshima J Med Sci. 1976 Sep ;25(2-3):135-40.

PubMed
Long-term therapy of myoclonus and other neurologic disorders with L-5-hydroxytr...
Long-term therapy of myoclonus and other neurologic disorders with L-5-hydroxytryptophan and carbidopa.
N Engl J Med. 1977 Jan 13 ;296(2):70-5.

PubMed
L-5HTP treatment and serum 5-HT level after L-5-HTP loading on depressed patient...
L-5HTP treatment and serum 5-HT level after L-5-HTP loading on depressed patients.
Neuropsychobiology. 1979 ;5(4):232-40.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to:

Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa.

Abstract

Publication Types, MeSH Terms, Substances, Grant Support

Publication Types

MeSH Terms

Substances

Grant Support

LinkOut - more resources

Full Text Sources

Medical

Molecular Biology Databases

Supplemental Content

Related citations

Cited by 10 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information